{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:56:07Z","timestamp":1790841367788,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100010340","name":"Lebanese American University","doi-asserted-by":"publisher","award":["PIRF I0054"],"award-info":[{"award-number":["PIRF I0054"]}],"id":[{"id":"10.13039\/100010340","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"DOI":"10.1007\/s11095-026-04215-z","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:25:26Z","timestamp":1790792726000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Platinum(IV) Complexes Suppress Tumor Growth in MDA-MB-231 Cells and a DMBA- Induced Mammary Carcinoma Model"],"prefix":"10.1007","author":[{"given":"Amjad","family":"Slika","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba","family":"Al Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joelle Bou","family":"Chacra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Haydar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris Abou","family":"Jaoude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe Bou","family":"Gharios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joya Maria","family":"Mrad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Mehanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria George","family":"Elias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishant M.","family":"Deo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin I.","family":"Taleb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice R.","family":"Aldrich-Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8275-7263","authenticated-orcid":false,"given":"Costantine F.","family":"Daher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"4215_CR1","unstructured":"\u201cBreast cancer,\u201d World Health Organization, 2025. [Online]. Available: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/breast-cancer"},{"key":"4215_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2024.177202","volume":"988","author":"L Xu","year":"2025","unstructured":"Xu L, Xu P, Wang J, Ji H, Zhang L, Tang Z. Advancements in clinical research and emerging therapies for triple-negative breast cancer treatment. Eur J Pharmacol. 2025;988:177202. https:\/\/doi.org\/10.1016\/j.ejphar.2024.177202.","journal-title":"Eur J Pharmacol"},{"issue":"7","key":"4215_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26072993","volume":"26","author":"N Garc\u00eda-Sancha","year":"2025","unstructured":"Garc\u00eda-Sancha N, Corchado-Cobos R, P\u00e9rez-Losada J. Understanding susceptibility to breast cancer: from risk factors to prevention strategies. Int J Mol Sci. 2025;26(7):2993. https:\/\/doi.org\/10.3390\/ijms26072993.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4215_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0111-2","volume":"5","author":"N Harbeck","year":"2019","unstructured":"Harbeck N, et al. Breast cancer. Nat Rev Dis Primers. 2019;5(1):66. https:\/\/doi.org\/10.1038\/s41572-019-0111-2.","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"4215_CR5","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321(3):288\u2013300. https:\/\/doi.org\/10.1001\/jama.2018.19323.","journal-title":"JAMA"},{"issue":"2","key":"4215_CR6","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","volume":"9","author":"AC Garrido-Castro","year":"2019","unstructured":"Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov. 2019;9(2):176\u201398. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-1177.","journal-title":"Cancer Discov"},{"key":"4215_CR7","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/205698a0","volume":"205","author":"B Rosenberg","year":"1965","unstructured":"Rosenberg B, Vancamp L, Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature. 1965;205:698\u20139. https:\/\/doi.org\/10.1038\/205698a0.","journal-title":"Nature"},{"issue":"4","key":"4215_CR8","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nrd1691","volume":"4","author":"D Wang","year":"2005","unstructured":"Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005;4(4):307\u201320. https:\/\/doi.org\/10.1038\/nrd1691.","journal-title":"Nat Rev Drug Discov"},{"issue":"15","key":"4215_CR9","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/onc.2011.384","volume":"31","author":"L Galluzzi","year":"2012","unstructured":"Galluzzi L, et al. Molecular mechanisms of cisplatin resistance. Oncogene. Apr.2012;31(15):1869\u201383. https:\/\/doi.org\/10.1038\/onc.2011.384.","journal-title":"Oncogene"},{"issue":"5","key":"4215_CR10","doi-asserted-by":"publisher","first-page":"3436","DOI":"10.1021\/acs.chemrev.5b00597","volume":"116","author":"TC Johnstone","year":"2016","unstructured":"Johnstone TC, Suntharalingam K, Lippard SJ. The next generation of platinum drugs: targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) prodrugs. Chem Rev. 2016;116(5):3436\u201386. https:\/\/doi.org\/10.1021\/acs.chemrev.5b00597.","journal-title":"Chem Rev"},{"issue":"33","key":"4215_CR11","doi-asserted-by":"publisher","first-page":"12983","DOI":"10.1039\/C6DT01414C","volume":"45","author":"D Gibson","year":"2016","unstructured":"Gibson D. Platinum(IV) anticancer prodrugs \u2013 hypotheses and facts. Dalton Trans. 2016;45(33):12983\u201391. https:\/\/doi.org\/10.1039\/C6DT01414C.","journal-title":"Dalton Trans"},{"issue":"6","key":"4215_CR12","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1002\/cmdc.201402074","volume":"9","author":"W Neumann","year":"2014","unstructured":"Neumann W, Crews BC, Marnett LJ, Hey-Hawkins E. Conjugates of cisplatin and cyclooxygenase inhibitors as potent antitumor agents overcoming cisplatin resistance. ChemMedChem. 2014;9(6):1150\u20133. https:\/\/doi.org\/10.1002\/cmdc.201402074.","journal-title":"ChemMedChem"},{"issue":"24","key":"4215_CR13","doi-asserted-by":"publisher","first-page":"8560","DOI":"10.1039\/c9dt00909d","volume":"48","author":"H Shi","year":"2019","unstructured":"Shi H, et al. Photoactive platinum(IV) complex conjugated to a cancer-cell-targeting cyclic peptide. Dalton Trans. 2019;48(24):8560\u20134. https:\/\/doi.org\/10.1039\/c9dt00909d.","journal-title":"Dalton Trans"},{"issue":"32","key":"4215_CR14","doi-asserted-by":"publisher","first-page":"5431","DOI":"10.1200\/JCO.2008.20.1228","volume":"27","author":"CN Sternberg","year":"2009","unstructured":"Sternberg CN, et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol. 2009;27(32):5431\u20138. https:\/\/doi.org\/10.1200\/JCO.2008.20.1228.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4215_CR15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.chembiol.2005.10.011","volume":"13","author":"PJ Bednarski","year":"2006","unstructured":"Bednarski PJ, Gr\u00fcnert R, Zielzki M, Wellner A, Mackay FS, Sadler PJ. Light-activated destruction of cancer cell nuclei by platinum diazide complexes. Chem Biol. 2006;13(1):61\u20137. https:\/\/doi.org\/10.1016\/j.chembiol.2005.10.011.","journal-title":"Chem Biol"},{"issue":"24","key":"4215_CR16","doi-asserted-by":"publisher","first-page":"16481","DOI":"10.1021\/acs.jmedchem.2c01310","volume":"65","author":"A Khoury","year":"2022","unstructured":"Khoury A, et al. Novel platinum(II) and platinum(IV) antitumor agents that exhibit potent cytotoxicity and selectivity. J Med Chem. 2022;65(24):16481\u201393. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c01310.","journal-title":"J Med Chem"},{"key":"4215_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2023.110834","volume":"388","author":"J Baz","year":"2024","unstructured":"Baz J, et al. Enhanced potency of a chloro-substituted polyaromatic platinum(II) complex and its platinum(IV) prodrug against lung cancer. Chem Biol Interact. 2024;388:110834. https:\/\/doi.org\/10.1016\/j.cbi.2023.110834.","journal-title":"Chem Biol Interact"},{"key":"4215_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.117734","volume":"294","author":"R Al Sayegh","year":"2025","unstructured":"Al Sayegh R, et al. The anti-neoplastic potency of epoxy-substituted polyaromatic platinum(II) and platinum(IV) complexes against A549 lung cancer cells. Eur J Med Chem. 2025;294:117734. https:\/\/doi.org\/10.1016\/j.ejmech.2025.117734.","journal-title":"Eur J Med Chem"},{"key":"4215_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.crphar.2024.100205","volume":"7","author":"A Slika","year":"2024","unstructured":"Slika A, et al. Unveiling the chemotherapeutic potential of two platinum(IV) complexes in skin cancer: in vitro and in vivo insights. Curr Res Pharmacol Drug Discov. 2024;7:100205. https:\/\/doi.org\/10.1016\/j.crphar.2024.100205.","journal-title":"Curr Res Pharmacol Drug Discov"},{"issue":"2","key":"4215_CR20","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1023\/a:1012414119944","volume":"69","author":"D Gallo","year":"2001","unstructured":"Gallo D, et al. \u201cChemoprevention of DMBA-induced mammary cancer in rats by dietary soy,.\u201d Breast Cancer Res Treat. 2001;69(2):153\u201364. https:\/\/doi.org\/10.1023\/a:1012414119944.","journal-title":"Breast Cancer Res Treat"},{"issue":"46","key":"4215_CR21","doi-asserted-by":"publisher","first-page":"17228","DOI":"10.1039\/C9DT04049H","volume":"48","author":"KM Deo","year":"2019","unstructured":"Deo KM, Sakoff J, Gilbert J, Zhang Y, Wright JRA. Synthesis, characterisation and influence of lipophilicity on cellular accumulation and cytotoxicity of unconventional platinum(IV) prodrugs as potent anticancer agents. Dalton Trans. 2019;48(46):17228\u201340. https:\/\/doi.org\/10.1039\/C9DT04049H.","journal-title":"Dalton Trans"},{"issue":"1","key":"4215_CR22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40620-017-0392-z","volume":"31","author":"S Manohar","year":"2018","unstructured":"Manohar S, Leung N. Cisplatin nephrotoxicity: a review of the literature. J Nephrol. 2018;31(1):15\u201325. https:\/\/doi.org\/10.1007\/s40620-017-0392-z.","journal-title":"J Nephrol"},{"issue":"2","key":"4215_CR23","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3892\/ijo.2018.4661","volume":"54","author":"V Schirrmacher","year":"2018","unstructured":"Schirrmacher V. From chemotherapy to biological therapy: a review of novel concepts to reduce the side effects of systemic cancer treatment (review). Int J Oncol. 2018;54(2):407\u201319. https:\/\/doi.org\/10.3892\/ijo.2018.4661.","journal-title":"Int J Oncol"},{"key":"4215_CR24","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2019.961","author":"C Pucci","year":"2019","unstructured":"Pucci C, Martinelli C, Ciofani G. Innovative approaches for cancer treatment: current perspectives and new challenges. ecancermedicalscience. 2019. https:\/\/doi.org\/10.3332\/ecancer.2019.961.","journal-title":"ecancermedicalscience"},{"issue":"3","key":"4215_CR25","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.toxlet.2015.06.012","volume":"237","author":"T Karasawa","year":"2015","unstructured":"Karasawa T, Steyger PS. An integrated view of cisplatin-induced nephrotoxicity and ototoxicity. Toxicol Lett. 2015;237(3):219\u201327. https:\/\/doi.org\/10.1016\/j.toxlet.2015.06.012.","journal-title":"Toxicol Lett"},{"issue":"9","key":"4215_CR26","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/sj.ki.5002786","volume":"73","author":"N Pabla","year":"2008","unstructured":"Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008;73(9):994\u20131007. https:\/\/doi.org\/10.1038\/sj.ki.5002786.","journal-title":"Kidney Int"},{"key":"4215_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/1462802","volume":"2018","author":"M Per\u0161e","year":"2018","unstructured":"Per\u0161e M, Ve\u010deri\u0107-Haler \u017d. Cisplatin-induced rodent model of kidney injury: characteristics and challenges. BioMed Res Int. 2018;2018:1\u201329. https:\/\/doi.org\/10.1155\/2018\/1462802.","journal-title":"BioMed Res Int"},{"issue":"19","key":"4215_CR28","doi-asserted-by":"publisher","first-page":"6645","DOI":"10.1039\/C8DT00838H","volume":"47","author":"R Oun","year":"2018","unstructured":"Oun R, Moussa YE, Wheate NJ. The side effects of platinum-based chemotherapy drugs: a review for chemists. Dalton Trans. 2018;47(19):6645\u201353. https:\/\/doi.org\/10.1039\/C8DT00838H.","journal-title":"Dalton Trans"},{"issue":"4","key":"4215_CR29","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/bjc.1987.75","volume":"55","author":"ZH Siddik","year":"1987","unstructured":"Siddik ZH, Boxall FE, Harrap KR. Haematological toxicity of carboplatin in rats. Br J Cancer. 1987;55(4):375\u20139. https:\/\/doi.org\/10.1038\/bjc.1987.75.","journal-title":"Br J Cancer"},{"issue":"1","key":"4215_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-022-00483-4","volume":"13","author":"JSN Shankara Narayanan","year":"2022","unstructured":"Shankara Narayanan JSN, et al. Oxaliplatin-induced peripheral neuropathy can be minimized by pressurized regional intravascular delivery in an orthotopic murine pancreatic cancer model. Discov Oncol. 2022;13(1):21. https:\/\/doi.org\/10.1007\/s12672-022-00483-4.","journal-title":"Discov Oncol"},{"issue":"1","key":"4215_CR31","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1039\/C2CS35259A","volume":"42","author":"X Wang","year":"2013","unstructured":"Wang X, Guo Z. Targeting and delivery of platinum-based anticancer drugs. Chem Soc Rev. 2013;42(1):202\u201324. https:\/\/doi.org\/10.1039\/C2CS35259A.","journal-title":"Chem Soc Rev"},{"issue":"12","key":"4215_CR32","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1002\/ejic.201601278","volume":"2017","author":"RG Kenny","year":"2017","unstructured":"Kenny RG, Chuah SW, Crawford A, Marmion CJ. Platinum(IV) prodrugs \u2013 a step closer to Ehrlich\u2019s vision? Eur J Inorg Chem. 2017;2017(12):1596\u2013612. https:\/\/doi.org\/10.1002\/ejic.201601278.","journal-title":"Eur J Inorg Chem"},{"key":"4215_CR33","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1146\/annurev.pharmtox.48.080907.180426","volume":"48","author":"MD Hall","year":"2008","unstructured":"Hall MD, Okabe M, Shen D-W, Liang X-J, Gottesman MM. The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol. 2008;48:495\u2013535. https:\/\/doi.org\/10.1146\/annurev.pharmtox.48.080907.180426.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"6","key":"4215_CR34","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1124\/mol.109.063172","volume":"77","author":"SB Howell","year":"2010","unstructured":"Howell SB, Safaei R, Larson CA, Sailor MJ. Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. Mol Pharmacol. 2010;77(6):887\u201394. https:\/\/doi.org\/10.1124\/mol.109.063172.","journal-title":"Mol Pharmacol"},{"issue":"1","key":"4215_CR35","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.drup.2010.12.002","volume":"14","author":"H Burger","year":"2011","unstructured":"Burger H, Loos WJ, Eechoute K, Verweij J, Mathijssen RHJ, Wiemer EAC. Drug transporters of platinum-based anticancer agents and their clinical significance. Drug Resist Updat Rev Comment Antimicrob Anticancer Chemother. 2011;14(1):22\u201334. https:\/\/doi.org\/10.1016\/j.drup.2010.12.002.","journal-title":"Drug Resist Updat Rev Comment Antimicrob Anticancer Chemother"},{"issue":"8","key":"4215_CR36","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrc2167","volume":"7","author":"L Kelland","year":"2007","unstructured":"Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007;7(8):573\u201384. https:\/\/doi.org\/10.1038\/nrc2167.","journal-title":"Nat Rev Cancer"},{"key":"4215_CR37","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/140284","author":"S G\u00f3mez-Ruiz","year":"2012","unstructured":"G\u00f3mez-Ruiz S, Maksimovi\u0107-Ivani\u0107 D, Mijatovi\u0107 S, Kalu\u0111erovi\u0107 GN. On the discovery, biological effects, and use of cisplatin and metallocenes in anticancer chemotherapy. Bioinorg Chem Appl. 2012. https:\/\/doi.org\/10.1155\/2012\/140284.","journal-title":"Bioinorg Chem Appl"},{"issue":"10","key":"4215_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/molecules24101995","volume":"24","author":"E Alessio","year":"1995","unstructured":"Alessio E, Messori L. NAMI-A and KP1019\/1339, two iconic ruthenium anticancer drug candidates face-to-face: a case story in medicinal inorganic chemistry. Molecules. 1995;24(10):1995. https:\/\/doi.org\/10.3390\/molecules24101995.","journal-title":"Molecules"},{"issue":"7","key":"4215_CR39","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nrd2803","volume":"8","author":"D Trachootham","year":"2009","unstructured":"Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov. 2009;8(7):579\u201391. https:\/\/doi.org\/10.1038\/nrd2803.","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"4215_CR40","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/nrd4002","volume":"12","author":"C Gorrini","year":"2013","unstructured":"Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov. 2013;12(12):931\u201347. https:\/\/doi.org\/10.1038\/nrd4002.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"4215_CR41","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.3390\/cancers3011351","volume":"3","author":"A-M Florea","year":"2011","unstructured":"Florea A-M, B\u00fcsselberg D. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers. 2011;3(1):1351\u201371. https:\/\/doi.org\/10.3390\/cancers3011351.","journal-title":"Cancers"},{"issue":"9","key":"4215_CR42","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/nprot.2009.120","volume":"4","author":"EL Abel","year":"2009","unstructured":"Abel EL, Angel JM, Kiguchi K, DiGiovanni J. Multi-stage chemical carcinogenesis in mouse skin: fundamentals and applications. Nat Protoc. 2009;4(9):1350\u201362. https:\/\/doi.org\/10.1038\/nprot.2009.120.","journal-title":"Nat Protoc"},{"issue":"39","key":"4215_CR43","doi-asserted-by":"publisher","first-page":"64289","DOI":"10.18632\/oncotarget.11733","volume":"7","author":"MC Abba","year":"2016","unstructured":"Abba MC, et al. DMBA induced mouse mammary tumors display high incidence of activating Pik3caH1047 and loss of function Pten mutations. Oncotarget. 2016;7(39):64289\u201399. https:\/\/doi.org\/10.18632\/oncotarget.11733.","journal-title":"Oncotarget"},{"key":"4215_CR44","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/bs.mcb.2020.09.003","volume":"163","author":"I Plante","year":"2021","unstructured":"Plante I. Dimethylbenz(a)anthracene-induced mammary tumorigenesis in mice. Methods Cell Biol. 2021;163:21\u201344. https:\/\/doi.org\/10.1016\/bs.mcb.2020.09.003.","journal-title":"Methods Cell Biol"},{"key":"4215_CR45","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.biopha.2018.04.027","volume":"103","author":"HE Daaboul","year":"2018","unstructured":"Daaboul HE, et al. The chemotherapeutic effect of \u03b2-2-himachalen-6-ol in chemically induced skin tumorigenesis. Biomed Pharmacother. 2018;103:443\u201352. https:\/\/doi.org\/10.1016\/j.biopha.2018.04.027.","journal-title":"Biomed Pharmacother"},{"key":"4215_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2020.112545","volume":"253","author":"W Shebaby","year":"2020","unstructured":"Shebaby W, et al. Himachalol induces apoptosis in B16-F10 murine melanoma cells and protects against skin carcinogenesis. J Ethnopharmacol. 2020;253:112545. https:\/\/doi.org\/10.1016\/j.jep.2020.112545.","journal-title":"J Ethnopharmacol"},{"key":"4215_CR47","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/5483791","author":"C Simsek","year":"2019","unstructured":"Simsek C, Esin E, Yalcin S. Metronomic chemotherapy: a systematic review of the literature and clinical experience. J Oncol. 2019. https:\/\/doi.org\/10.1155\/2019\/5483791.","journal-title":"J Oncol"},{"issue":"9","key":"4215_CR48","doi-asserted-by":"publisher","first-page":"8560","DOI":"10.1021\/acsnano.7b04092","volume":"11","author":"RJ Browning","year":"2017","unstructured":"Browning RJ, et al. Drug delivery strategies for platinum-based chemotherapy. ACS Nano. 2017;11(9):8560\u201378. https:\/\/doi.org\/10.1021\/acsnano.7b04092.","journal-title":"ACS Nano"},{"issue":"6","key":"4215_CR49","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s00280-016-2976-z","volume":"77","author":"S Dilruba","year":"2016","unstructured":"Dilruba S, Kalayda GV. Platinum-based drugs: past, present and future. Cancer Chemother Pharmacol. 2016;77(6):1103\u201324. https:\/\/doi.org\/10.1007\/s00280-016-2976-z.","journal-title":"Cancer Chemother Pharmacol"},{"key":"4215_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00245","volume":"9","author":"K Nurgali","year":"2018","unstructured":"Nurgali K, Jagoe RT, Abalo R. Editorial: adverse effects of cancer chemotherapy: anything new to improve tolerance and reduce sequelae? Front Pharmacol. 2018;9:245. https:\/\/doi.org\/10.3389\/fphar.2018.00245.","journal-title":"Front Pharmacol"},{"issue":"10","key":"4215_CR51","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/nrd3801","volume":"11","author":"PY Muller","year":"2012","unstructured":"Muller PY, Milton MN. The determination and interpretation of the therapeutic index in drug development. Nat Rev Drug Discov. 2012;11(10):751\u201361. https:\/\/doi.org\/10.1038\/nrd3801.","journal-title":"Nat Rev Drug Discov"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04215-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-026-04215-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04215-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:04:44Z","timestamp":1790838284000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-026-04215-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":51,"alternative-id":["4215"],"URL":"https:\/\/doi.org\/10.1007\/s11095-026-04215-z","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"28 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}